Navigation Links
CEL-SCI Corporation Announces 2008 Financial Results
Date:1/14/2009

harmaceuticals and Orient Europharma), joint ventures and/or financings to start the Phase III clinical trial with its cancer drug Multikine. In addition, in late December 2008 CEL-SCI put in place a $5 million equity line of credit. In the meantime, in light of the challenging capital markets, management has been very successful in reducing its monthly cash expenditures.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

Multikine is also the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer. It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated. Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response. Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.

                                CEL-SCI CORPORATION
                        CONSOLIDATED STATEMENTS OF OPERATIONS
                       YEARS ENDED SEPTEMBER 30, 2008 and 2007

   
'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
3. CEL-SCI Takes Delivery of New Manufacturing Facility
4. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
6. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
7. CEL-SCI to Present at the Noble Financial Conference
8. Volcano Corporation Presentation at J.P. Morgan Conference to be Webcast
9. Mach One Corporation Enters Letter of Intent
10. Shareholder Class Action Filed Against Elan Corporation, plc by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
11. Environmental Tectonics Corporation Announces Placement of Two Monoplace Chambers at St. John Wound Center; First Computer-controlled Hyperbaric Chambers in Oklahoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/28/2014)... August 28, 2014 SPIE Fellow Glenn ... and Optical Science and Director of the Center for ... Carolina at Charlotte, and co-founder and Chairman of the ... as the 2015 Vice President of SPIE, the international ... Philip Stahl announced recent election results at the Annual ...
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... $59.0 Million, Up 46 Percent Over Third Quarter ... 2006, - Third Quarter EPS of $0.70 per Basic ... $1.19 per Diluted ... Share, SILVER SPRING, Md., Nov. 1 United,Therapeutics Corporation (Nasdaq: UTHR ) today announced ...
... (Nasdaq: NBIX ) today announced that it has ... commercialization of indiplon,in Japan with Dainippon Sumitomo Pharma Co, ... for indiplon in the US for the,treatment of insomnia. ... with a,PUDFA action date of December 12, 2007. ...
... Biopure Corporation,(Nasdaq: BPUR ) announced today the pricing ... to closing conditions, the,underwriters have agreed to purchase from ... warrants to acquire an additional 16,850,000,new shares. The price ... the,exercise price of each warrant is $1.06. This transaction ...
Cached Biology Technology:United Therapeutics Reports Third Quarter 2007 Financial Results 2United Therapeutics Reports Third Quarter 2007 Financial Results 3United Therapeutics Reports Third Quarter 2007 Financial Results 4United Therapeutics Reports Third Quarter 2007 Financial Results 5United Therapeutics Reports Third Quarter 2007 Financial Results 6United Therapeutics Reports Third Quarter 2007 Financial Results 7United Therapeutics Reports Third Quarter 2007 Financial Results 8United Therapeutics Reports Third Quarter 2007 Financial Results 9Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan 2Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan 3Biopure Announces Pricing of Equity Offering 2
(Date:8/29/2014)... species of marine phytoplankton, such as the prolific bloomer ... B1 (thiamine), researchers have discovered. The finding contradicts the ... other eukaryotic microbes depend on scarce supplies of thiamine ... different way to think about the ocean," says CIFAR ... The ISME Journal paper with CIFAR fellows ...
(Date:8/28/2014)... Society of America (ESA) is pleased to announce the ... of the Society. Honorary Membership acknowledges those who have ... involvement in the affairs of the Society that has ... selected by the ESA Governing Board and then voted ... honored at the Awards Ceremony at Entomology 2014, ESA,s ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research Careers) ... American Society of Human Genetics from October 18 ... are meant to promote the entry of students, post ... of the basic science community and to encourage the ... Human Genetics. This year MARC conferred 16 awards ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... A tissue-repair-and-regeneration pathway in the human body, including ... develop properly. Genetically engineered mice fail to develop ... Wnt2b, are knocked out. The findings are described this ... to know the answer to a seemingly simple question: ...
... NOAA Fisheries scallop survey off the northeastern U.S. coast ... "recruit" sea scallops and ocean quahogs on Georges Bank ... Mid-Atlantic for 2009. This survey, which included the first ... underwater imaging system from the same vessel, also shows ...
... have discovered the first protein-based toxin in an amphibian a ... Chinese tree frog. This finding may help shed more light ... poison. While gene-encoded protein toxins have been identified ... have yet been found in amphibians or birds. In the ...
Cached Biology News:How to make a lung 2Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic 2Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic 3Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic 4
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap. (2/sp, 20/ca) Packaging: 2 / pack, 20 /...
... Yeast Protein Kit is a simple and convenient ... cells. The kit has been optimized for use ... be used for any fungus species that is ... digestion procedure effectively generates spheroplasts of yeast cells ...
... series combines Harvard Apparatuss best pump mechanism, a ... range of configuration options. A lookup table in ... from all the major manufacturers. A bright, two ... information from across the lab. All models have ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
Biology Products: